Biosimulation Market Overview

The global Biosimulation Market is expected to witness robust growth, expanding from USD 4.27 billion in 2026 to USD 9.24 billion by 2031, at a CAGR of 16.7% during the forecast period.

The market is being driven by the increasing complexity of drug discovery and development, rising pharmaceutical R&D expenditures, growing emphasis on reducing clinical trial failures, and the widespread adoption of model-informed drug development (MIDD). Advances in physiologically based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology (QSP), population PK/PD modeling, and artificial intelligence (AI) are enabling pharmaceutical and biotechnology companies to make faster, data-driven decisions while reducing development risks and costs.

As regulatory agencies increasingly recognize the value of biosimulation in drug evaluation, demand for sophisticated modeling platforms is expected to accelerate significantly.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=838

What Is Biosimulation?

Biosimulation is the application of mathematical modeling, computer simulations, pharmacology, systems biology, and artificial intelligence to predict how drugs interact with biological systems.

Rather than relying solely on laboratory experiments or clinical trials, biosimulation enables researchers to create virtual models that simulate:

• Drug absorption, distribution, metabolism, and excretion (ADME)
• Drug efficacy and safety
• Disease progression
• Drug-drug interactions
• Dose optimization
• Patient population variability
• Clinical trial outcomes

These simulations help pharmaceutical companies make better decisions throughout the drug development lifecycle while reducing time, cost, and clinical risk.

Biosimulation Market Overview

Market Indicator	Value
Market Size (2026)	USD 4.27 Billion
Forecast Market Size (2031)	USD 9.24 Billion
CAGR (2026–2031)	16.7%
Forecast Period	2026–2031

The increasing integration of AI, cloud computing, and predictive analytics into biosimulation platforms is expected to drive sustained market growth.

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=838

Key Factors Driving Market Growth

Increasing Complexity of Drug Discovery

Modern therapeutics—including biologics, gene therapies, cell therapies, and precision medicines—require sophisticated computational models to understand complex biological interactions.

Biosimulation enables researchers to:

• Identify promising drug candidates
• Predict biological responses
• Reduce laboratory testing
• Improve candidate selection
• Accelerate development timelines

Rising Pharmaceutical R&D Costs

Drug development remains one of the most expensive and time-consuming processes in healthcare.

Biosimulation helps organizations reduce costs by:

• Eliminating low-potential candidates early
• Optimizing preclinical studies
• Reducing unnecessary clinical trials
• Improving trial design
• Supporting regulatory submissions

These efficiencies significantly improve return on R&D investment.

Growing Adoption of Model-Informed Drug Development (MIDD)

Model-Informed Drug Development (MIDD) has become a cornerstone of modern pharmaceutical research.

MIDD combines computational models with clinical and biological data to support:

• Dose selection
• Trial optimization
• Regulatory decision-making
• Drug labeling
• Patient stratification

The growing acceptance of MIDD by regulatory agencies is accelerating adoption worldwide.

Expansion of PBPK and QSP Modeling

Advanced modeling approaches are transforming pharmaceutical development.

Physiologically Based Pharmacokinetic (PBPK) Modeling

PBPK models simulate how drugs move through different organs and tissues, enabling researchers to:

• Predict drug-drug interactions
• Optimize dosing strategies
• Evaluate special patient populations
• Support regulatory submissions

Quantitative Systems Pharmacology (QSP)

QSP combines systems biology with pharmacology to model disease mechanisms and predict therapeutic responses, supporting more informed decision-making during drug development.

Artificial Intelligence Enhancing Biosimulation

Artificial intelligence is increasingly integrated into biosimulation platforms to:

• Automate model development
• Improve predictive accuracy
• Analyze complex biological datasets
• Accelerate simulation workflows
• Enhance decision-making

AI-powered biosimulation is reducing development timelines while improving the quality of predictive models.

Regulatory Support Accelerating Adoption

Global regulatory agencies are increasingly recognizing biosimulation as an essential component of drug development.

Notable developments include:

• The US Food and Drug Administration (FDA) continues to encourage the use of PBPK modeling for predicting drug-drug interactions and supporting dosing recommendations.
• The International Council for Harmonisation (ICH) introduced the M15 Guideline on Model-Informed Drug Development (MIDD), promoting standardized approaches to modeling and simulation across global regulatory submissions.

These initiatives are increasing confidence in biosimulation technologies and encouraging broader industry adoption.

Market Challenges

Despite strong growth prospects, several factors continue to restrain market expansion.

High Implementation Costs

Deploying advanced biosimulation platforms requires significant investment in software, computing infrastructure, and specialized personnel.

Shortage of Skilled Professionals

The market faces an ongoing shortage of experts in:

• Pharmacometrics
• Systems biology
• Computational modeling
• AI-driven drug development
• Bioinformatics

This talent gap may slow implementation across some organizations.

Model Validation and Regulatory Acceptance

Although regulatory support is increasing, organizations must still demonstrate the reliability, reproducibility, and scientific validity of computational models.

Data Integration Complexity

Combining biological, pharmacological, genomic, clinical, and real-world data into unified simulation platforms remains technically challenging.

Emerging Trends

Several technological innovations are shaping the future of the Biosimulation Market.

AI-Driven Model Development

Machine learning algorithms are automating model generation while improving predictive accuracy.

Digital Twins in Drug Development

Virtual patient models are enabling researchers to simulate disease progression and treatment responses before initiating clinical studies.

Cloud-Based Biosimulation Platforms

Cloud infrastructure enables global collaboration, scalable computing, and faster simulation workflows.

Precision Medicine Integration

Biosimulation is increasingly supporting personalized therapies by integrating genomic, biomarker, and clinical data into predictive models.

Virtual Clinical Trials

Simulation-based trial design is helping pharmaceutical companies optimize protocols, reduce patient recruitment challenges, and improve trial efficiency.

Competitive Landscape

The Biosimulation Market is highly competitive, with leading companies investing in AI, cloud technologies, strategic collaborations, acquisitions, and next-generation modeling platforms.

Major market participants include:

• Certara (US)
• Dassault Systèmes (France)
• Schrödinger, Inc. (US)
• Simulations Plus (US)
• Advanced Chemistry Development, Inc. (Revvity) (Canada)

These companies continue expanding their capabilities through product innovation, strategic partnerships, acquisitions, and global expansion.

Company Profiles

Certara (US)

Certara is recognized as a global leader in biosimulation, offering an extensive portfolio of solutions spanning:

• Model-Informed Drug Development (MIDD)
• Physiologically Based Pharmacokinetic (PBPK) Modeling
• Quantitative Systems Pharmacology (QSP)
• Regulatory Science
• Clinical Pharmacology

Its platforms help pharmaceutical and biotechnology companies optimize candidate selection, predict drug safety and efficacy, improve dose selection, and streamline regulatory submissions.

The company continues to strengthen its leadership through AI integration. In October 2025, Certara introduced an AI-enabled QSP platform designed to automate model development, improve predictive performance, and simplify the analysis of complex biological systems.

In May 2026, Certara announced a strategic partnership with Altasciences to combine biosimulation expertise with preclinical and clinical development capabilities, helping sponsors accelerate drug development while reducing development risks.

Dassault Systèmes (France)

Dassault Systèmes provides advanced biosimulation capabilities through its 3DEXPERIENCE Platform and comprehensive Life Sciences Solutions Portfolio.

Its technologies support:

• Virtual experiments
• Disease modeling
• Drug development optimization
• Digital twins
• Clinical decision support

The company continues expanding its platform by incorporating:

• Artificial intelligence
• Cloud collaboration
• Virtual twin technology

Strategic acquisitions and collaborations continue strengthening Dassault Systèmes’ position within the global life sciences ecosystem.

Schrödinger, Inc. (US)

Schrödinger has established a strong position in biosimulation through its computational platform that combines:

• Physics-based molecular modeling
• Artificial intelligence
• Machine learning
• Predictive simulation
• Computational chemistry

Its technologies help pharmaceutical companies accelerate:

• Target identification
• Lead optimization
• Candidate selection
• Drug design
• Clinical success prediction

In January 2026, Schrödinger partnered with Eli Lilly to integrate its TuneLab platform into the LiveDesign environment, enabling advanced protein engineering, molecular design, and collaborative therapeutic development within a unified digital workspace.

Regional Analysis

North America

North America currently leads the Biosimulation Market due to:

• Strong pharmaceutical R&D investments
• Early adoption of AI technologies
• Supportive regulatory environment
• Presence of major biosimulation vendors
• Extensive clinical research infrastructure

Europe

Europe remains a significant market supported by:

• Advanced pharmaceutical manufacturing
• Strong academic research
• Regulatory harmonization
• Growing digital health initiatives

Asia Pacific

Asia Pacific is expected to experience the fastest growth during the forecast period owing to:

• Expanding biotechnology sector
• Increasing pharmaceutical outsourcing
• Rising clinical research activities
• Government support for life sciences innovation
• Growing investments in computational biology

Future Outlook

The Biosimulation Market is expected to play an increasingly central role in pharmaceutical innovation as AI, digital twins, and computational biology become integral to drug development. Future advancements are likely to include:

• Generative AI-assisted model creation
• Multi-scale biological simulations
• Integration of real-world evidence (RWE)
• AI-powered virtual clinical trials
• Cloud-native collaborative modeling platforms
• Personalized digital patient simulations
• Automated regulatory modeling workflows

These innovations will enable faster, more efficient, and more precise development of next-generation therapeutics.

Conclusion

The global Biosimulation Market is entering a period of rapid expansion, fueled by the increasing complexity of drug development, rising R&D costs, and widespread adoption of AI-powered modeling technologies. With the market projected to reach USD 9.24 billion by 2031 at a CAGR of 16.7%, biosimulation is becoming an indispensable tool for pharmaceutical, biotechnology, and research organizations seeking to improve clinical success rates, reduce development timelines, and make more informed scientific and regulatory decisions. As computational modeling, AI, and regulatory acceptance continue to evolve, biosimulation will remain a cornerstone of the future of precision drug development.

Inquire Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=838